Action 17 | Paediatric HIV

AdobeStock_330370789 - 3.jpg

HIV TREATMENT

2020

Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:

Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Paediatric HIV & TB : Rome Action Plan

Action 17

Engage in early and regular consultations with the PAWG on PIP/PSPs, as well as recommended dosing and ratios for FDC development.

Committed by:

Pharmaceutical companies

Sub-Actions & Milestones

Sub-action 17.2

Recommend dosing and ratios for FDC development.

-

-

-

Milestone 17.2.1

-

-

-

-

Document (s)

-

-

-

-

Sub-action 17.1

Engage in early and regular consultations with the PAWG on PIP/PSPs

Pharmaceutical Companies

-

-

Milestone 17.1.1

-

-

-

-

Document (s)

-

-

-

-

Updates

Notes

Responsible